22/09/2025
is a very dangerous disease of the abdomen, as very often it brings symptoms at very advanced stages.
The importance of the ongoing OVHIPEC-2, a multi-institutional Phase III randomized Trial, involving patients with advanced ovarian cancer undergoing surgery without prior chemotherapy, is putting together the efforts on many significant Oncological Centers like Akademiska sjukhuset - Uppsala University Hospital.
The first results are expected in 2026.
For additional information, please visit us at:
www.rand-biotech.com
https://via.tt.se/pressmeddelande/4045306/ny-forskning-visar-hipec-behandling-kan-forlanga-overlevnaden-vid-spridd-aggstockscancer?publisherId=3235843&lang=sv
2022 var Akademiska sjukhuset först i Sverige med att introducera varm cytostatika i buken, HIPEC, som behandling vid spridd äggstockscancer. Målgruppen var patienter som opereras utan förbehandling med cytostatika och behandlingen gavs inom ramen för en studie. Nu pågår en annan studie, OVHI...